Abstract
The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.
| Original language | English |
|---|---|
| Pages (from-to) | 432-438 |
| Number of pages | 7 |
| Journal | Biology of Blood and Marrow Transplantation |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2009 |
Fingerprint
Keywords
- Allogeneic transplantation
- High-dose chemotherapy
- Hodgkin lymphoma
- Salvage chemotherapy
ASJC Scopus subject areas
- Transplantation
- Hematology
Cite this
Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma. / Castagna, Luca; Sarina, Barbara; Todisco, Elisabetta; Magagnoli, Massimo; Balzarotti, Monica; Bramanti, Stefania; Mazza, Rita; Anastasia, Antonella; Bacigalupo, Andrea; Aversa, Franco; Soligo, Davide; Giordano, Laura; Santoro, Armando.
In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 4, 04.2009, p. 432-438.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma
AU - Castagna, Luca
AU - Sarina, Barbara
AU - Todisco, Elisabetta
AU - Magagnoli, Massimo
AU - Balzarotti, Monica
AU - Bramanti, Stefania
AU - Mazza, Rita
AU - Anastasia, Antonella
AU - Bacigalupo, Andrea
AU - Aversa, Franco
AU - Soligo, Davide
AU - Giordano, Laura
AU - Santoro, Armando
PY - 2009/4
Y1 - 2009/4
N2 - The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.
AB - The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.
KW - Allogeneic transplantation
KW - High-dose chemotherapy
KW - Hodgkin lymphoma
KW - Salvage chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=61749102653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61749102653&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2008.12.506
DO - 10.1016/j.bbmt.2008.12.506
M3 - Article
C2 - 19285630
AN - SCOPUS:61749102653
VL - 15
SP - 432
EP - 438
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 4
ER -